{"success":true,"data":{"pressRelease":{"id":"130638","rtpr_id":"nNFC3lZ061","ticker":"NUMIF","exchange":"OTC","all_tickers":["NUMIF"],"title":"Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update","author":"Newsfile Corp","published_at":"2026-08-28T21:00:10.432Z","article_body":"Q4 Fiscal 2025 Highlights\n* Revenue of $2.3 million, a 29.0% increase over Q3 2025\n* Gross profit of $1.4 million, compared to a gross profit of $0.8 million in\nQ3 2025\n* Cash position of $0.5 million as of August 31, 2025\nSubsequent to Quarter End\n* On April 18, 2026, President Donald Trump signed an executive order\ndirecting U.S. federal agencies to accelerate research, access, and regulatory\nreview for psychedelic-based treatments, including psilocybin, ibogaine, MDMA,\nand LSD, and committing US$50 million in federal support for state-level\nprograms. The Company views this as a meaningful regulatory development for\nits clinical research operations and practitioner training programs, both of\nwhich are actively engaged in psychedelic research delivery and practitioner\nreadiness. The ultimate impact, however, will depend on further agency\nimplementation by the FDA and DEA.\nAll financial results are reported in Canadian dollars unless otherwise\nstated.\n\nVancouver, British Columbia--(Newsfile Corp. - August 28, 2026) - Numinus\nWellness Inc. (https://api.newsfilecorp.com/redirect/87VO1TmgQW) (OTC Pink:\nNUMIF) (\"Numinus\" or the \"Company\") a mental health care company focused on\ninnovative behavioral health treatments with a focus on safe, evidence-based\npsychedelic-assisted therapies, today announced its financial results for the\nthree months and year ended August 31, 2025 (\"Q4 2025\").\n\nRevenue from continuing operations\nThe Company's consolidated revenues increased by 29.0% quarter over quarter\ncompared to Q3 2025.\n\nRevenues from Cedar Clinical Research (\"CCR\") operations during Q4 2025\ndecreased by 13.2% from $1.6 million during Q3 2025 to $1.4 million as a\nresult of seasonality impacts relating to clinical trial patients.\n\nRevenues from Practitioner Training during Q4 2025 increased by 387.6% from\n$0.2 million during Q3 2025 to $1.0 million. The increase in revenue was due\nto the ramp up of strategic contracts with a research partner to help support\nthe training efforts of various psychedelic clinical trials.\n\nGross Margin\nGross margin in Q4 2025 was 61.2%, compared to a gross profit of 48.3% in Q3\n2025.\n\nOperating expenditures\nOperating expenditures and other items were $2.9 million in Q4 2025, compared\nto $1.7 million in the previous quarter. The increase is a result of the\nCompany's ongoing cost containment initiatives and operational optimization.\n\nOperational Highlights\nNuminus Clinical Research\n\nRevenues from CCR during Q4 2025 were $1.4 million, a decrease of 13.2%\ncompared to Q3 2025.\n\nCCR managed 18 clinical trials, including 306 patient appointments in Q4 2025,\ncompared to 15 clinical trials and 233 patient appointments in Q3 2025.\n\nPractitioner Training\n\nPractitioner Training revenue increased by 387.6% in Q4 2025 to $1.0 million\ncompared to $0.2 million in Q3 2025.\n\nPractitioner Training reached a milestone profit of $1.2 million during the\nyear ended August 31, 2025, compared to a loss of $47,837 during the year\nended August 31, 2024.\n\nBalance Sheet and Liquidity\nNuminus ended the quarter with cash and cash equivalents of $0.5 million and a\nworking capital deficiency of $2.7 million.\n\nQ4 2025 Performance Metrics\n\n                                       For the quarter ended:                                                       \n                                       August 31, 2025  (Q4 2025)         May 31, 2025  (Q3 2025)         % change  \n Total Revenue                         $2,325,321                         $1,802,942                      29.0%     \n Cost of revenue                       902,926                            932,842                         -3.2%     \n Gross Profit (Loss)                   $1,422,395                         $870,100                        63.5%     \n Gross profit margin (loss)            61.2%                              48.3%                           2680 bps  \n Operating expenses and other items    2,882,259                          1,667,279                       71.8%     \n Loss and comprehensive loss           ($881,837)                         ($741,575)                      n/a       \n\n \n\nNuminus' consolidated financial statements for the year ended August 31, 2025,\nand related management's discussion and analysis are available on Numinus'\nInvestor Relations website at www.investors.numinusnetwork.com and under the\nCompany's profile on SEDAR+ at www.sedarplus.ca. These documents were prepared\nin accordance with IFRS.\n\nFinancial Reporting Update\nThe Company continues to advise that the completion of the August 31, 2025,\naudit, together with the imminent filing of the Company’s outstanding\ninterim financial reports, is a central component of management’s plan to\nsatisfy the regulatory requirements necessary to have the cease trade order\nthat is currently in place with respect to the Company (the “CTO”)\nrevoked.\n\nManagement remains focused on completing the remaining interim financial\nreports, satisfying all regulatory requirements necessary to have the CTO\nrevoked, and advancing the Company's previously announced application to list\nits common shares on the Canadian Securities Exchange (the \"CSE\").\nSuccessfully executing these steps remains management's primary strategy to\nrestore trading, enhance shareholder liquidity, and position the Company for\nits next phase of growth. A listing on the CSE will be contingent on the\nCompany satisfying the CSE’s listing requirements and being approved for\nlisting on that exchange.\n\nBoard Appointment\nThe Company is pleased to announce the appointment of John Fong, former CFO of\nNuminus Wellness Inc., as a member of the Company's Board of Directors and the\nBoard's Audit Committee. Following his departure from Numinus, Mr. Fong\nfounded F28 Studio, a fractional CFO practice serving high-growth companies.\nF28 turns legacy tools and structures into intelligent systems using AI. Mr.\nFong is an independent member of the Board of Directors and its Audit\nCommittee, as well as being financially literate (among other reasons, in\nlight of his prior experience as CFO of the Company).\n\nAbout Numinus\nNuminus Wellness Inc. (OTC Pink: NUMIF) helps people to heal and be well\nthrough the development and delivery of innovative mental health care and\naccess to safe, evidence-based psychedelic-assisted therapies. The Numinus\nmodel – including psychedelic research and training – is at the\nforefront of a transformation aimed at healing rather than managing symptoms\nfor depression, anxiety, trauma, pain and substance use. At Numinus, we are\nleading the integration of psychedelic-assisted therapies into mainstream\nclinical practice and building the foundation for a healthier society.\n\nLearn more at www.numinusnetwork.com and follow us on LinkedIn\n(https://api.newsfilecorp.com/redirect/ZEyLzCpWYG), Facebook\n(https://api.newsfilecorp.com/redirect/anyvmT1NEZ), Twitter\n(https://api.newsfilecorp.com/redirect/24bnRu5XMy), and Instagram\n(https://api.newsfilecorp.com/redirect/Mq3LvSMrVe).\n\nSOURCE Numinus Wellness Inc.\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\napplicable securities laws. All statements that are not historical facts,\nincluding, without limitation, statements regarding future estimates, plans,\nprograms, forecasts, projections, objectives, assumptions, expectations or\nbeliefs regarding future performance are \"forward-looking statements\".\nForward-looking statements can be identified by the use of words such as\n\"expects\", \"does not expect\", \"is expected\", \"believes\", \"intends\",\n\"anticipates\", \"does not anticipate\", \"believes\" or variations of these words,\nexpressions or statements, that certain actions, events or results \"may\",\n\"could\", \"would\", \"might\" or \"will be\" taken, will occur or will be realized.\nSuch forward-looking statements involve risks, uncertainties and other known\nand unknown factors that could cause actual results, events or developments to\ndiffer materially from the results, events or developments expected and\nexpressed or implied in such forward-looking statements. These and other risk\nfactors are outlined in our annual information form dated July 25, 2025, which\nis available on SEDAR+ at www.sedarplus.ca. These factors should be carefully\nconsidered, and readers are cautioned not to place undue reliance on\nforward-looking statements. Despite the Company's efforts to identify the main\nrisk factors that could cause actual measures, events or results to differ\nmaterially from those described in forward-looking statements, other risk\nfactors may cause measures, events or developments to materially differ from\nthose anticipated, estimated or intended. There can be no assurance that\nforward-looking statements will prove to be accurate, as actual results and\nfuture events could differ materially from those anticipated in\nforward-looking statements. The Company does not undertake to revise\nforward-looking statements, even if new information becomes available as a\nresult of future events, new facts or any other reason, except as required by\napplicable laws.\n\nFor more information:\nInvestor Contact\nCraig MacPhail\ninvest@numinusnetwork.com\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/311976","article_body_html":"","raw_payload":{"data":{"id":"nNFC3lZ061","title":"Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update","author":"Newsfile Corp","ticker":"NUMIF","created":"2026-08-28T21:00:10.432Z","tickers":["NUMIF"],"exchange":"OTC","article_body":"Q4 Fiscal 2025 Highlights\n* Revenue of $2.3 million, a 29.0% increase over Q3 2025\n* Gross profit of $1.4 million, compared to a gross profit of $0.8 million in\nQ3 2025\n* Cash position of $0.5 million as of August 31, 2025\nSubsequent to Quarter End\n* On April 18, 2026, President Donald Trump signed an executive order\ndirecting U.S. federal agencies to accelerate research, access, and regulatory\nreview for psychedelic-based treatments, including psilocybin, ibogaine, MDMA,\nand LSD, and committing US$50 million in federal support for state-level\nprograms. The Company views this as a meaningful regulatory development for\nits clinical research operations and practitioner training programs, both of\nwhich are actively engaged in psychedelic research delivery and practitioner\nreadiness. The ultimate impact, however, will depend on further agency\nimplementation by the FDA and DEA.\nAll financial results are reported in Canadian dollars unless otherwise\nstated.\n\nVancouver, British Columbia--(Newsfile Corp. - August 28, 2026) - Numinus\nWellness Inc. (https://api.newsfilecorp.com/redirect/87VO1TmgQW) (OTC Pink:\nNUMIF) (\"Numinus\" or the \"Company\") a mental health care company focused on\ninnovative behavioral health treatments with a focus on safe, evidence-based\npsychedelic-assisted therapies, today announced its financial results for the\nthree months and year ended August 31, 2025 (\"Q4 2025\").\n\nRevenue from continuing operations\nThe Company's consolidated revenues increased by 29.0% quarter over quarter\ncompared to Q3 2025.\n\nRevenues from Cedar Clinical Research (\"CCR\") operations during Q4 2025\ndecreased by 13.2% from $1.6 million during Q3 2025 to $1.4 million as a\nresult of seasonality impacts relating to clinical trial patients.\n\nRevenues from Practitioner Training during Q4 2025 increased by 387.6% from\n$0.2 million during Q3 2025 to $1.0 million. The increase in revenue was due\nto the ramp up of strategic contracts with a research partner to help support\nthe training efforts of various psychedelic clinical trials.\n\nGross Margin\nGross margin in Q4 2025 was 61.2%, compared to a gross profit of 48.3% in Q3\n2025.\n\nOperating expenditures\nOperating expenditures and other items were $2.9 million in Q4 2025, compared\nto $1.7 million in the previous quarter. The increase is a result of the\nCompany's ongoing cost containment initiatives and operational optimization.\n\nOperational Highlights\nNuminus Clinical Research\n\nRevenues from CCR during Q4 2025 were $1.4 million, a decrease of 13.2%\ncompared to Q3 2025.\n\nCCR managed 18 clinical trials, including 306 patient appointments in Q4 2025,\ncompared to 15 clinical trials and 233 patient appointments in Q3 2025.\n\nPractitioner Training\n\nPractitioner Training revenue increased by 387.6% in Q4 2025 to $1.0 million\ncompared to $0.2 million in Q3 2025.\n\nPractitioner Training reached a milestone profit of $1.2 million during the\nyear ended August 31, 2025, compared to a loss of $47,837 during the year\nended August 31, 2024.\n\nBalance Sheet and Liquidity\nNuminus ended the quarter with cash and cash equivalents of $0.5 million and a\nworking capital deficiency of $2.7 million.\n\nQ4 2025 Performance Metrics\n\n                                       For the quarter ended:                                                       \n                                       August 31, 2025  (Q4 2025)         May 31, 2025  (Q3 2025)         % change  \n Total Revenue                         $2,325,321                         $1,802,942                      29.0%     \n Cost of revenue                       902,926                            932,842                         -3.2%     \n Gross Profit (Loss)                   $1,422,395                         $870,100                        63.5%     \n Gross profit margin (loss)            61.2%                              48.3%                           2680 bps  \n Operating expenses and other items    2,882,259                          1,667,279                       71.8%     \n Loss and comprehensive loss           ($881,837)                         ($741,575)                      n/a       \n\n \n\nNuminus' consolidated financial statements for the year ended August 31, 2025,\nand related management's discussion and analysis are available on Numinus'\nInvestor Relations website at www.investors.numinusnetwork.com and under the\nCompany's profile on SEDAR+ at www.sedarplus.ca. These documents were prepared\nin accordance with IFRS.\n\nFinancial Reporting Update\nThe Company continues to advise that the completion of the August 31, 2025,\naudit, together with the imminent filing of the Company’s outstanding\ninterim financial reports, is a central component of management’s plan to\nsatisfy the regulatory requirements necessary to have the cease trade order\nthat is currently in place with respect to the Company (the “CTO”)\nrevoked.\n\nManagement remains focused on completing the remaining interim financial\nreports, satisfying all regulatory requirements necessary to have the CTO\nrevoked, and advancing the Company's previously announced application to list\nits common shares on the Canadian Securities Exchange (the \"CSE\").\nSuccessfully executing these steps remains management's primary strategy to\nrestore trading, enhance shareholder liquidity, and position the Company for\nits next phase of growth. A listing on the CSE will be contingent on the\nCompany satisfying the CSE’s listing requirements and being approved for\nlisting on that exchange.\n\nBoard Appointment\nThe Company is pleased to announce the appointment of John Fong, former CFO of\nNuminus Wellness Inc., as a member of the Company's Board of Directors and the\nBoard's Audit Committee. Following his departure from Numinus, Mr. Fong\nfounded F28 Studio, a fractional CFO practice serving high-growth companies.\nF28 turns legacy tools and structures into intelligent systems using AI. Mr.\nFong is an independent member of the Board of Directors and its Audit\nCommittee, as well as being financially literate (among other reasons, in\nlight of his prior experience as CFO of the Company).\n\nAbout Numinus\nNuminus Wellness Inc. (OTC Pink: NUMIF) helps people to heal and be well\nthrough the development and delivery of innovative mental health care and\naccess to safe, evidence-based psychedelic-assisted therapies. The Numinus\nmodel – including psychedelic research and training – is at the\nforefront of a transformation aimed at healing rather than managing symptoms\nfor depression, anxiety, trauma, pain and substance use. At Numinus, we are\nleading the integration of psychedelic-assisted therapies into mainstream\nclinical practice and building the foundation for a healthier society.\n\nLearn more at www.numinusnetwork.com and follow us on LinkedIn\n(https://api.newsfilecorp.com/redirect/ZEyLzCpWYG), Facebook\n(https://api.newsfilecorp.com/redirect/anyvmT1NEZ), Twitter\n(https://api.newsfilecorp.com/redirect/24bnRu5XMy), and Instagram\n(https://api.newsfilecorp.com/redirect/Mq3LvSMrVe).\n\nSOURCE Numinus Wellness Inc.\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\napplicable securities laws. All statements that are not historical facts,\nincluding, without limitation, statements regarding future estimates, plans,\nprograms, forecasts, projections, objectives, assumptions, expectations or\nbeliefs regarding future performance are \"forward-looking statements\".\nForward-looking statements can be identified by the use of words such as\n\"expects\", \"does not expect\", \"is expected\", \"believes\", \"intends\",\n\"anticipates\", \"does not anticipate\", \"believes\" or variations of these words,\nexpressions or statements, that certain actions, events or results \"may\",\n\"could\", \"would\", \"might\" or \"will be\" taken, will occur or will be realized.\nSuch forward-looking statements involve risks, uncertainties and other known\nand unknown factors that could cause actual results, events or developments to\ndiffer materially from the results, events or developments expected and\nexpressed or implied in such forward-looking statements. These and other risk\nfactors are outlined in our annual information form dated July 25, 2025, which\nis available on SEDAR+ at www.sedarplus.ca. These factors should be carefully\nconsidered, and readers are cautioned not to place undue reliance on\nforward-looking statements. Despite the Company's efforts to identify the main\nrisk factors that could cause actual measures, events or results to differ\nmaterially from those described in forward-looking statements, other risk\nfactors may cause measures, events or developments to materially differ from\nthose anticipated, estimated or intended. There can be no assurance that\nforward-looking statements will prove to be accurate, as actual results and\nfuture events could differ materially from those anticipated in\nforward-looking statements. The Company does not undertake to revise\nforward-looking statements, even if new information becomes available as a\nresult of future events, new facts or any other reason, except as required by\napplicable laws.\n\nFor more information:\nInvestor Contact\nCraig MacPhail\ninvest@numinusnetwork.com\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/311976"},"type":"article","timestamp":"2026-08-28T21:00:10.499785539Z","server_sent_at_ms":1787950810499},"received_at":"2026-08-28T21:00:10.563Z","source_url":"https://www.newsfilecorp.com/release/311976"},"analysis":{"id":"119543","press_release_id":"130638","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":["Working capital deficiency of $2.7 million","Cash position of only $0.5 million","Cease trade order currently in place","Operating expenses increased 72% quarter-over-quarter"],"eventType":"earnings","narrative":"Numinus reported Q4 fiscal 2025 revenue of $2.3 million, up 29% from the prior quarter, with gross margin expanding to 61.2% driven primarily by a 388% surge in practitioner training revenue.\n\nDespite the operational growth, the company faces severe liquidity constraints, ending the quarter with a cash balance of $0.5 million and a working capital deficiency of $2.7 million.\n\nThe company remains subject to a cease trade order and is focused on completing its outstanding audit and satisfying regulatory requirements to restore trading on the Canadian Securities Exchange.","sentiment":"mixed","agentHooks":{"shouldPost":false,"suggestedAngle":"Operational momentum continues, but liquidity and the active Cease Trade Order remain the critical focus for shareholders."},"keyFigures":{"revenue":2325321,"customDimensions":{"net_loss":881837,"gross_margin":"61.2%","gross_profit":1422395,"operating_expenses":2882259,"revenue_growth_qoq":"29.0%","working_capital_deficiency":2700000}},"quotedText":"The ultimate impact, however, will depend on further agency implementation by the FDA and DEA.","namedEntities":{"people":[{"name":"Donald Trump","role":"U.S. President"},{"name":"John Fong","role":"Board Member"},{"name":"Craig MacPhail","role":"Investor Contact"}],"products":["psilocybin","ibogaine","MDMA","LSD"],"companies":[{"name":"Numinus Wellness Inc.","ticker":"NUMIF"},{"name":"Cedar Clinical Research","relationship":"subsidiary"},{"name":"F28 Studio","relationship":"founded by board member"}],"dollarAmounts":[{"amount":"$2.3 million","context":"Q4 fiscal 2025 revenue"},{"amount":"$1.4 million","context":"Q4 gross profit"},{"amount":"$0.5 million","context":"cash and cash equivalents"},{"amount":"US$50 million","context":"federal support for state-level psychedelic programs"}]},"materialImpact":{"score":3,"reasoning":"Operational improvements with 29% sequential revenue growth and expanding margins are overshadowed by a critical working capital deficiency, low cash balance, and the ongoing Cease Trade Order which limits trading."},"tickerRelevance":{"others":[],"primary":"NUMIF"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":["board_change"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"earnings_with_cto","sectorWeight":"niche_healthcare"}},"event_type":"earnings","event_type_secondary":["board_change"],"sentiment":"mixed","material_impact_score":3,"narrative":"Numinus reported Q4 fiscal 2025 revenue of $2.3 million, up 29% from the prior quarter, with gross margin expanding to 61.2% driven primarily by a 388% surge in practitioner training revenue.\n\nDespite the operational growth, the company faces severe liquidity constraints, ending the quarter with a cash balance of $0.5 million and a working capital deficiency of $2.7 million.\n\nThe company remains subject to a cease trade order and is focused on completing its outstanding audit and satisfying regulatory requirements to restore trading on the Canadian Securities Exchange.","key_figures":{"revenue":2325321,"customDimensions":{"net_loss":881837,"gross_margin":"61.2%","gross_profit":1422395,"operating_expenses":2882259,"revenue_growth_qoq":"29.0%","working_capital_deficiency":2700000}},"named_entities":{"people":[{"name":"Donald Trump","role":"U.S. President"},{"name":"John Fong","role":"Board Member"},{"name":"Craig MacPhail","role":"Investor Contact"}],"products":["psilocybin","ibogaine","MDMA","LSD"],"companies":[{"name":"Numinus Wellness Inc.","ticker":"NUMIF"},{"name":"Cedar Clinical Research","relationship":"subsidiary"},{"name":"F28 Studio","relationship":"founded by board member"}],"dollarAmounts":[{"amount":"$2.3 million","context":"Q4 fiscal 2025 revenue"},{"amount":"$1.4 million","context":"Q4 gross profit"},{"amount":"$0.5 million","context":"cash and cash equivalents"},{"amount":"US$50 million","context":"federal support for state-level psychedelic programs"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-28T21:05:26.463Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"earnings_with_cto","sectorWeight":"niche_healthcare"}},"durationMs":175487,"modelName":"glm-4.7"}}